{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:14:43Z","timestamp":1785402883703,"version":"3.56.0"},"reference-count":132,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is clinically heterogeneous. Patients with similar body mass index, waist circumference, or noninvasive fibrosis stratum may differ markedly in histologic activity, fibrosis trajectory, and progression risk. Adipose tissue dysfunction helps explain this variation. Adipose dysfunction has been characterized by direct depot quantification, measurement of subcutaneous adipose tissue fibrogenesis, adipose tissue insulin resistance, and circulating adipokine profiles. These measures capture different features of adipose biology and have each been linked to liver injury or fibrosis severity. Clinically recognizable body-composition phenotypes\u2014lean MASLD, sarcopenic visceral obesity, myosteatosis, and the hypertriglyceridemic waist\u2014differ in accessibility, mechanistic specificity, and prognostic value. Recent therapeutic developments in metabolic dysfunction-associated steatohepatitis (MASH), including resmetirom, semaglutide, tirzepatide, fibroblast growth factor 21 (FGF21) analogs, and older adipose-directed agents such as pioglitazone, illustrate the importance of distinguishing adipose-mediated, weight-mediated, and liver-directed mechanisms. This review summarizes the literature on adipose tissue dysfunction in MASLD, the body-composition phenotypes associated with it, and recent therapeutic data in the context of adipose\u2013liver\u2013muscle biology.<\/jats:p>","DOI":"10.3390\/cells15151377","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:09:42Z","timestamp":1785398982000},"page":"1377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2035-3024","authenticated-orcid":false,"given":"Andrew John Legaspi","family":"Cruz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Los Angeles County + USC Medical Center, Los Angeles, CA 90033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Los Angeles County + USC Medical Center, Los Angeles, CA 90033, USA"},{"name":"Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of USC, Los Angeles, CA 90033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: The need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00535-024-02093-z","article-title":"Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Wakabayashi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12072-025-10801-x","article-title":"Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: A systematic review and meta-analysis","volume":"19","author":"Cheah","year":"2025","journal-title":"Hepatol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cld.1183","article-title":"Nonalcoholic Fatty Liver Disease: The role of visceral adipose tissue","volume":"19","author":"Hanlon","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, X., Rao, H.Y., Liu, F., Wei, L., Li, H., and Wu, C. (2021). Recent advances in adipose tissue dysfunction and its role in the pathogenesis of non-alcoholic fatty liver disease. Cells, 10.","DOI":"10.3390\/cells10123300"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.15377","article-title":"Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals","volume":"42","author":"Saponaro","year":"2022","journal-title":"Liver Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH\u2014Role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/CS20140553","article-title":"Normal weight individuals who develop type 2 diabetes: The personal fat threshold","volume":"128","author":"Taylor","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0711","DOI":"10.1097\/HC9.0000000000000711","article-title":"Skeletal muscle and MASLD: Mechanistic and clinical insights","volume":"9","author":"Marjot","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.jhepr.2023.100963","article-title":"Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease","volume":"6","author":"Henin","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Barbalho, S.M., Laurindo, L.F., Valenti, V.E., M\u00e9ndez-S\u00e1nchez, N., Ram\u00edrez-Mej\u00eda, M.M., and de Alvares Goulart, R. (2025). Organokine-mediated crosstalk: A systems biology perspective on the pathogenesis of MASLD\u2014A narrative review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311547"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of MASLD and MASH on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","article-title":"How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?","volume":"15","author":"Geng","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.31822","article-title":"Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease","volume":"74","author":"Beals","year":"2021","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"155759","DOI":"10.1016\/j.metabol.2023.155759","article-title":"Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD","volume":"151","author":"Bilson","year":"2024","journal-title":"Metabolism"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1042\/CS20230586","article-title":"Aetiology of type 2 diabetes in people with a \u2018normal\u2019 body mass index: Testing the personal fat threshold hypothesis","volume":"137","author":"Taylor","year":"2023","journal-title":"Clin. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome\u2014An allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: From new variants to the clinic","volume":"72","author":"Valenti","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","article-title":"A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis","volume":"285","author":"He","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.29273","article-title":"The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation","volume":"66","author":"BasuRay","year":"2017","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"154028","DOI":"10.1016\/j.metabol.2019.154028","article-title":"Adiponectin and leptin in the diagnosis and therapy of NAFLD","volume":"103","author":"Boutari","year":"2020","journal-title":"Metabolism"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2159","DOI":"10.1097\/MD.0000000000002159","article-title":"Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ismaiel, A., and Dumitrascu, D.L. (2021). The visceral adiposity index in non-alcoholic fatty liver disease and liver fibrosis: A systematic review and meta-analysis. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121890"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ncb2922","article-title":"Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source","volume":"16","author":"Chau","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cmet.2013.03.008","article-title":"Mechanisms and metabolic implications of regional differences among fat depots","volume":"17","author":"Tchkonia","year":"2013","journal-title":"Cell Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.ijo.0800789","article-title":"Catecholamine-induced lipolysis in obesity","volume":"23","author":"Arner","year":"1999","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1467-789X.2012.01035.x","article-title":"Visceral fat and metabolic inflammation: The portal theory revisited","volume":"13","author":"Item","year":"2012","journal-title":"Obes. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI45887","article-title":"Adipose tissue remodeling and obesity","volume":"121","author":"Sun","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1194\/jlr.M500294-JLR200","article-title":"Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans","volume":"46","author":"Cinti","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1128\/MCB.00192-09","article-title":"Hypoxia-inducible factor 1\u03b1 induces fibrosis and insulin resistance in white adipose tissue","volume":"29","author":"Halberg","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/MCB.01300-08","article-title":"Metabolic dysregulation and adipose tissue fibrosis: Role of collagen VI","volume":"29","author":"Khan","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.jhepr.2024.101092","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hep.25805","article-title":"Relationship between adipose tissue insulin resistance and liver histology in NASH: A PIVENS follow-up study","volume":"56","author":"Bell","year":"2012","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1210\/clinem\/dgac660","article-title":"Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD","volume":"108","author":"Kalavalapalli","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: Common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s42255-019-0041-z","article-title":"Metabolic Messengers: Adiponectin","volume":"1","author":"Straub","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nm1557","article-title":"Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions","volume":"13","author":"Yamauchi","year":"2007","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrm2249","article-title":"AMP-activated\/SNF1 protein kinases: Conserved guardians of cellular energy","volume":"8","author":"Hardie","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.24119","article-title":"Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver","volume":"53","author":"Asahina","year":"2011","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5483\/BMBRep.2024-0058","article-title":"Neutrophils in MASLD and MASH","volume":"58","author":"Shrestha","year":"2025","journal-title":"BMB Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/HEP.0000000000000762","article-title":"Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC","volume":"81","author":"Xia","year":"2025","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/gutjnl-2023-331447","article-title":"Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis","volume":"73","author":"Babuta","year":"2024","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image","volume":"97","author":"Shen","year":"2004","journal-title":"J. Appl. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e222008","DOI":"10.1148\/radiol.222008","article-title":"AI-based CT body composition identifies myosteatosis as key mortality predictor in asymptomatic adults","volume":"307","author":"Nachit","year":"2023","journal-title":"Radiology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cgh.2022.01.020","article-title":"Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression","volume":"21","author":"Hsieh","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3350\/cmh.2023.0035","article-title":"Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s10238-025-01865-y","article-title":"Sarcopenic visceral obesity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"25","author":"Elsabaawy","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/hep4.1435","article-title":"Fat accumulation, liver fibrosis, and metabolic abnormalities in Chinese patients with moderate\/severe versus mild hepatic steatosis","volume":"3","author":"Zhang","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Iwaki, M., Kobayashi, T., Nogami, A., Saito, S., Nakajima, A., and Yoneda, M. (2023). Impact of sarcopenia on non-alcoholic fatty liver disease. Nutrients, 15.","DOI":"10.3390\/nu15040891"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1377-3","article-title":"Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease","volume":"53","author":"Shida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/00365521.2021.1879244","article-title":"Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity","volume":"56","author":"Shi","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/hep4.1975","article-title":"Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex","volume":"6","author":"Cho","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Xing, M., Ni, Y., Zhang, Y., Zhao, X., and Yu, X. (2023). The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1246157"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Su, X., Xu, J., and Zheng, C. (2019). The relationship between non-alcoholic fatty liver and skeletal muscle mass to visceral fat area ratio in women with type 2 diabetes. BMC Endocr. Disord., 19.","DOI":"10.1186\/s12902-019-0404-1"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2229139","DOI":"10.1155\/2022\/2229139","article-title":"The association of sarcopenia and visceral obesity with lean nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12944-024-02100-5","article-title":"Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population","volume":"23","author":"Liu","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e13569","DOI":"10.1111\/1753-0407.13569","article-title":"Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017\u20132018","volume":"16","author":"Mai","year":"2024","journal-title":"J. Diabetes"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5009\/gnl230238","article-title":"Appendicular skeletal muscle mass to visceral fat area ratio predicts hepatic morbidities","volume":"18","author":"Han","year":"2024","journal-title":"Gut Liver"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/hep.30049","article-title":"Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study","volume":"68","author":"Kim","year":"2018","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1017\/S0007114521002415","article-title":"Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease","volume":"127","author":"Li","year":"2022","journal-title":"Br. J. Nutr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101544","DOI":"10.1016\/j.aohep.2024.101544","article-title":"Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis","volume":"29","author":"Malik","year":"2024","journal-title":"Ann. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","article-title":"The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis","volume":"43","author":"Li","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/jcsm.13543","article-title":"Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography","volume":"15","author":"Kim","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"100323","DOI":"10.1016\/j.jhepr.2021.100323","article-title":"A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients","volume":"3","author":"Nachit","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e15398","DOI":"10.14814\/phy2.15398","article-title":"MRI characterization of skeletal muscle size and fatty infiltration in long-term trained and untrained individuals","volume":"10","author":"Emanuelsson","year":"2022","journal-title":"Physiol. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jcsm.12646","article-title":"Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models","volume":"12","author":"Nachit","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Pasmans, K., Adriaens, M.E., Olinga, P., Langen, R., Rensen, S.S., Schaap, F.G., Olde Damink, S.W.M., Caiment, F., van Loon, L.J.C., and Blaak, E.E. (2021). Hepatic steatosis contributes to the development of muscle atrophy via inter-organ crosstalk. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.733625"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1038\/s41467-023-41832-3","article-title":"Metabolic crosstalk between skeletal muscle cells and liver through IRF4-FSTL1 in nonalcoholic steatohepatitis","volume":"14","author":"Guo","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(10)60408-4","article-title":"Lipid-induced insulin resistance: Unravelling the mechanism","volume":"375","author":"Samuel","year":"2010","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa031314","article-title":"Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes","volume":"350","author":"Petersen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12587","DOI":"10.1073\/pnas.0705408104","article-title":"The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome","volume":"104","author":"Petersen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1152\/jappl.2001.90.6.2157","article-title":"Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study","volume":"90","author":"Goodpaster","year":"2001","journal-title":"J. Appl. Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s10620-025-08844-z","article-title":"Clinical relevancies of sarcopenic obesity in patients with metabolic dysfunction-associated fatty liver disease (MASLD)","volume":"70","author":"Chien","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1007\/s10620-025-09107-7","article-title":"Sarcopenic obesity and MASLD: A dangerous duo driving deadly cardiometabolic risk","volume":"70","author":"Channapragada","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Chen, M., Cao, Y., Ji, G., and Zhang, L. (2023). Lean nonalcoholic fatty liver disease and sarcopenia. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1217249"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-\u03b1 or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.jhep.2021.01.025","article-title":"Sarcopenia and frailty in decompensated cirrhosis","volume":"75","author":"Tandon","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/lt.25346","article-title":"Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease","volume":"25","author":"Bhanji","year":"2019","journal-title":"Liver Transpl."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3748\/wjg.v30.i8.956","article-title":"Prevalence and clinical impact of sarcopenia in liver transplant recipients: A meta-analysis","volume":"30","author":"Jiang","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.mce.2014.11.029","article-title":"The sexual dimorphism of obesity","volume":"402","author":"Palmer","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_96","unstructured":"U.S. Food and Drug Administration (2026, May 09). FDA Approves First Treatment for Patients with Liver Scarring due to Fatty Liver Disease, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_98","unstructured":"U.S. Food and Drug Administration (2026, May 09). FDA Approves Treatment for Serious Liver Disease Known as MASH, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"ref_101","unstructured":"Tripathi, R., Gupta, S., Jarnes, L., Zeidan, N., Tao, M., and Jamorabo, D. (2025, January 24\u201329). Efficacy of GLP-1 receptor agonists in MASH resolution and fibrosis reduction: A meta-analysis. Abstract P3746. Proceedings of the ACG 2025 Annual Scientific Meeting, Phoenix, AZ, USA."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e70034","DOI":"10.1002\/psp4.70034","article-title":"Model-Based Meta-Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction-Associated Steatohepatitis Patients","volume":"15","author":"Tran","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: The diverse biology of PPAR\u03b3","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1101\/gad.177857.111","article-title":"FGF21 regulates PGC-1\u03b1 and browning of white adipose tissues in adaptive thermogenesis","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes Dev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/dc25-1306","article-title":"Relationship between metabolic and histological responses in people with metabolic dysfunction-associated steatohepatitis with and without type 2 diabetes: Participant-level exploratory analysis of the SYNERGY-NASH trial with tirzepatide","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/en.2011-1070","article-title":"Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance","volume":"152","author":"Vendrell","year":"2011","journal-title":"Endocrinology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2169\/internalmedicine.7134-21","article-title":"Effects of canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"60","author":"Nishimiya","year":"2021","journal-title":"Intern. Med."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Tokubuchi, I., Tajiri, Y., Iwata, S., Hara, K., Wada, N., Hashinaga, T., Nakayama, H., Mifune, H., and Yamada, K. (2017). Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171293"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjms.2024.10.005","article-title":"Effect of therapeutic lifestyle changes on patients with overweight\/obesity and non-alcoholic fatty liver disease: A randomized controlled trial","volume":"369","author":"Huang","year":"2025","journal-title":"Am. J. Med. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/apt.70382","article-title":"Effects of resmetirom on metabolic dysfunction-associated steatohepatitis in patients with weight loss and\/or diabetes taking glucagon-like peptide-1 receptor agonists and other diabetes therapies: A secondary analysis of the MAESTRO-NASH trial","volume":"62","author":"Noureddin","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro [1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"M\u00e1tis, D., Hegyi, P., Teutsch, B., Tornai, T., Er\u0151ss, B., P\u00e1r, G., and V\u00e1ncsa, S. (2023). Improved body composition decreases the fat content in non-alcoholic fatty liver disease: A meta-analysis and systematic review of longitudinal studies. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1114836"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/lt.26071","article-title":"Reduction of visceral adiposity as a predictor for resolution of nonalcoholic fatty liver in potential living liver donors","volume":"27","author":"Lee","year":"2021","journal-title":"Liver Transpl."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:26:33Z","timestamp":1785399993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":132,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151377"],"URL":"https:\/\/doi.org\/10.3390\/cells15151377","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}